Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIVI-II: Microplasmin for PVD Induction in Diabetic Macular Edema
NCT00412451Phase 2Completed
- Sponsor
- Oxurion
- Start
- Dec 2006
- Primary completion
- Jan 2010
- Modality
- Therapeutic Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ocriplasmin in diabetic macular edema (DME) (4 arms), sponsored by Oxurion. Primary endpoint: Posterior Vitreous Detachment Induction at 14 days. Started Dec 2006; status: completed.
02
Drugs
ocriplasmin
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00412451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412451.